JonesResearch analyst Debanjana Chatterjee raised the firm’s price target on Sagimet Biosciences (SGMT) to $27 from $15 and keeps a Buy rating on the shares. The company reported a positive readout from denifanstat’s Ascletis-partnered Phase 3 acne program, the analyst tells investors in a research note. The firm says its check-in with acne doctor John Barbieri from Harvard Medical School suggests a “highly competitive profile” for FASN inhibition in acne. It now has increased confidence in the mechanism of action as well as the drug’s market size.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Promising Potential of Sagimet Biosciences: Buy Rating Affirmed by Positive Phase 3 Trial Results and Strategic Advancements
- Sagimet Biosciences Announces Phase 3 Trial Success
- Sagimet Biosciences to host KOL event on denifanstat, resmetirom
- Sagimet Biosciences, Inc.: A Promising Investment in the NASH Market with Strategic Growth Initiatives
- Sagimet Biosciences price target lowered to $25 from $30 at Oppenheimer